卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白表达的影响

doi:10.11958/20220150

天津医药 ›› 2022, Vol. 50 ›› Issue (8): 873-877.doi: 10.11958/20220150

卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白表达的影响

胡加海¹(), 薛松¹, 陈荃²

1安徽医科大学附属滁州医院（滁州市第一人民医院）肿瘤内二科（邮编239000）
2安徽医科大学附属滁州医院（滁州市第一人民医院）内科（邮编239000）

收稿日期:2022-01-26 修回日期:2022-02-28 出版日期:2022-08-15 发布日期:2022-08-12
作者简介:胡加海（1974）,男,副主任医师,主要从事肿瘤相关疾病研究。E-mail： 2579309340@qq.com

Effects of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin in patients with advanced esophageal cancer

HU Jiahai¹(), XUE Song¹, CHEN Quan²

1 The Second Department of Medical Oncology, the Affiliated Chuzhou Hospital of Anhui Medical University (The First People’s Hospital of Chuzhou), Chuzhou 239000, China
2 Department of General Internal Medicine, the Affiliated Chuzhou Hospital of Anhui Medical University (The First People’s Hospital of Chuzhou), Chuzhou 239000, China

Received:2022-01-26 Revised:2022-02-28 Published:2022-08-15 Online:2022-08-12

胡加海, 薛松, 陈荃. 卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白表达的影响[J]. 天津医药, 2022, 50(8): 873-877.

HU Jiahai, XUE Song, CHEN Quan. Effects of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin in patients with advanced esophageal cancer[J]. Tianjin Medical Journal, 2022, 50(8): 873-877.

摘要/Abstract

摘要：

目的探讨卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白（sE-Cad）表达的影响。方法中晚期食管癌患者110例按用药方案不同分为联合组（57例）和化疗组（53例）。化疗组患者接受紫杉醇（260 mg/m²）+顺铂（30 mg/m²）方案治疗,联合组在此基础上接受卡瑞利珠单抗（200 mg/次,1次/2周）治疗。治疗4~6个周期后,评估2组总体疗效;酶联免疫吸附试验法检测血清肿瘤标志物、sE-Cad水平,实时荧光定量聚合酶链反应检测血清miR-21水平;记录治疗期间不良反应发生情况。结果治疗后,联合组患者的客观有效率（ORR）为70.18%,疾病控制率（DCR）为91.23%,高于化疗组的45.28%和77.36%（P<0.05）;治疗后联合组血清糖类抗原125（CA125）、癌胚抗原（CEA）、鳞状细胞癌相关性抗原（SCC）、miR-21和sE-Cad水平均明显低于化疗组（P<0.05）;治疗期间,联合组的反应性毛细血管增生症发生率高于化疗组（P<0.01）。结论卡瑞利珠单抗联合化疗方案治疗中晚期食管癌近期疗效良好,可有效降低肿瘤标志物水平,下调miR-21、sE-Cad在血清中的表达。

关键词: 食管肿瘤, 药物疗法,联合, 抗肿瘤联合化疗方案, 分子靶向治疗, 生物标记,肿瘤, 卡瑞利珠单抗, miR-21, 可溶性E-钙黏蛋白

Abstract:

Objective To investigate the effect of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin (sE-Cad) in patients with advanced esophageal cancer. Methods A total of 110 patients with advanced esophageal cancer were divided into the combination group (57 cases) and the chemotherapy group (53 cases) according to different therapeutic regimens. Patients in the chemotherapy group were treated with paclitaxel (260 mg/m²) and cisplatin (30 mg/m²) for chemotherapy, while those in the combination group were additionally treated with camrelizumab (200 mg every time, once every 2 weeks) on this basis. The overall curative effect was evaluated after 4-6 cycles of treatment. The serum levels of tumor markers and sE-Cad were detected by enzyme linked immunosorbent assay, and the serum level of miR-21 was detected by real-time fluorescence quantitative polymerase chain reaction. The incidence of adverse reactions during treatment was recorded. Results After treatment, the objective response rate (ORR) and disease control rate (DCR) were higher in the combination group than those in the chemotherapy group (70.18% vs. 45.28% and 91.23% vs. 77.36%, P<0.05). The serum levels of carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), squamous cell carcinoma-related antigens (SCC), miR-21 and sE-Cad were significantly lower in the combination group than those in the chemotherapy group (P<0.05). During treatment, the incidence of reactive capillary endothelial proliferation was higher in the combination group than that of the chemotherapy group (P<0.01). Conclusion Camrelizumab combined with chemotherapy has good short-term efficacy in the treatment of advanced esophageal cancer, which can effectively reduce levels of tumor markers, down-regulate serum miR-21 and sE-Cad.

Key words: esophageal neoplasms, drug therapy, combination, antineoplastic combined chemotherapy protocols, molecular targeted therapy, biomarkers, tumor, Camrelizumab, miR-21, soluble E-cadherin

中图分类号:

R735.1

图/表 6

表1 2组患者基线资料比较

Tab.1 Comparison of baseline data between the 2 groups

表2 2组患者一般资料比较 [例（%）]

Tab.2 Comparison of general data between the 2 groups

表3 2组患者总体疗效比较 [例（%）]

Tab.3 Comparison of overall curative effect between the 2 groups

表4 2组患者治疗前后血清肿瘤标志物水平比较（$\bar{x}±s$）

Tab.4 Comparison of serum tumor marker levels before and after treatment between the 2 groups

表5 2组患者治疗前后血清miR-21、sE-Cad水平比较（$\bar{x}±s$）

Tab.5 Comparison of serum miR-21 and sE-Cad levels before and after treatment between the 2 groups

表6 2组患者治疗期间不良反应发生情况比较 [例（%）]

Tab.6 Comparison of adverse reactions during treatment between the 2 groups

参考文献 23

[1]	HAUGE T, AMDAL C D, FALK R S, et al. Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer-A cohort study[J]. Acta Oncologica, 2020, 18(3):1-7. doi: 10.1080/0284186X.2020.1750694.
[2]	ZHANG D M, LI C S, CHENG N T, et al. CircAGFG1 acts as a sponge of miR-4306 to stimulate esophageal cancer progression by modulating MAPRE2 expression[J]. Acta Histochem, 2021, 123(7):151776. doi: 10.1016/j.acthis.2021.151776.
[3]	BOLLSCHWEILER E, PLUM P, MÖNIG S P, et al. Current and future treatment options for esophageal cancer in the elderly[J]. Expert Opin Pharmacother, 2017, 18(10):1001-1010. doi: 10.1080/14656566.2017.1334764.
[4]	PUETZ K, BOLLSCHWEILER E, SEMRAU R, et al. Neoadjuvant chemoradiation for patients with advanced esophageal cancer-Which response grading system best impacts prognostic discrimination?[J]. Histopathology, 2019, 74(5):731-743. doi: 10.1111/his.13811.
[5]	STILES B M, KAMEL M K, HARRISON S W, et al. Neoadjuvant therapy for locally advanced esophageal cancer should be targeted to tumor histology[J]. Ann Thorac Surg, 2019, 107(1):187-193. doi: 10.1016/j.athoracsur.2018.07.089.
[6]	ZIV G, SALEM B. Pembrolizumab-chemotherapy for advanced oesophageal cancer[J]. Lancet, 2021, 398(10302):726-727. doi: 10.1016/S0140-6736(21)01607-X.
[7]	刘润泽, 常栋, 李博闻. 食管鳞癌免疫治疗的临床进展[J]. 中华肿瘤防治杂志, 2021, 28(13):1028-1032.
	LIU R Z, CHANG D, LI B W. Clinical progress of immunotherapy for esophageal squamous cell carcinoma[J]. Chinese Journal of Cancer Prevention and Treatment, 2021, 28(13):1028-1032. doi: 10.16073/j.cnki.cjcpt.2021.13.11.
[8]	肖勇, 霍前伦, 杨祎明, 等. 卡瑞利珠单抗注射剂联合手术治疗Ⅱ/Ⅲ期食管鳞状细胞癌患者的临床研究[J]. 中国临床药理学杂志, 2021, 37(24):3323-3325.
	XIAO Y, HUO Q L, YANG Y M, et al. Clinical study of camrelizumab injection combined with surgery in the treatment of patients with stage Ⅱ/Ⅲ esophageal squamous cell carcinoma[J]. Chinese Journal of Clinical Pharmacology, 2021, 37(24):3323-3325. doi: 10.13699/j.cnki.1001-6821.2021.24.005.
[9]	LIU L, ZHANG X, ZHOU L H, et al. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer:A case report[J]. Medicine, 2021, 100(35):e27138. doi: 10.1097/MD.0000000000027138.
[10]	梁云微, 连相尧, 党春艳, 等. microRNA-21在食管癌细胞增殖,迁移和凋亡中的作用[J]. 基因组学与应用生物学, 2020, 39(2):845-851.
	LIANG Y W, LIAN X Y, DANG C Y, et al. Roles of microRNA-21 in proliferation,migration and apoptosis of esophageal cancer cells[J]. Genomics and Applied Biology, 2020, 39(2):845-851. doi: 10.13417/j.gab.039.000845.
[11]	NISHIOKA C, IKEZOE T, PAN B, et al. MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells[J]. Cancer Sci, 2017, 108(4):685-695. doi: 10.1111/cas.13170.
[12]	项敏敏, 任伟芳, 方忠宏, 等. 卡瑞利珠单抗联用阿帕替尼致药物性肝损伤1例[J]. 中国新药与临床杂志, 2021, 40(7):542-544.
	XIANG M M, REN W F, FANG Z H, et al. A case of drug induced liver injury caused by camrelizumab combined with apatinib[J]. Chinese Journal of New Drugs and Clinical Remedies, 2021, 40(7):542-544. doi: 10.14109/j.cnki.xyylc.2021.07.13.
[13]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. doi: 10.1016/S1359-6349(09)70018-7.
[14]	颜芳, 应明真, 陈龙佩, 等. 白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J]. 中国癌症杂志, 2020, 30(8):632-635.
	YAN F, YING M Z, CHEN L P, et al. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients[J]. China Oncology, 2020, 30(8):632-635. doi: 10.19401/j.cnki.1007-3639.2020.08.011.
[15]	ZENG H M, CHEN W Q, ZHENG R S, et al. Changing cancer survival in China during 2003-15:A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567. doi: 10.1016/S2214-109X(18)30127-X.
[16]	王文辉, 段旭华, 李浩, 等. 食管动脉化疗栓塞联合卡瑞利珠单抗治疗中晚期食管癌[J]. 中国介入影像与治疗学, 2021, 18(11):699-701.
	WANG W H, DUAN X H, LI H, et al. Chemoembolization of esophageal artery combined with Camrelizumab for treatment of advanced esophageal cancers[J]. Chinese Journal of Interventional Imaging and Therapy, 2021, 18(11):699-701. doi: 10.13929/j.issn.1672-8475.2021.11.014.
[17]	GUZIK K, TOMALA M, MUSZAK D, et al. Development of the inhibitors that target the PD-1/PD-L1 interaction-A brief look at progress on small molecules, peptides and macrocycles[J]. Molecules, 2019, 24(11): E2071. doi: 10.3390/molecules24112071.
[18]	CHEN Y L, CHANG M C, CHENG W F. Metronomic chemotherapy and immunotherapy in cancer treatment[J]. Cancer Lett, 2017, 400(1):282-292. doi: 10.1016/j.canlet.2017.01.040.
[19]	MO H N, HUANG J, XU J C, et al. Safety,anti-tumour activity,and pharmacokinetics of fixed-dose SHR-1210,an anti-PD-1 antibody in advanced solid tumours:A dose-escalation,phase 1 study[J]. Br J Cancer, 2018, 119(5):538-545. doi: 10.1038/s41416-018-0100-3.
[20]	宋琪, 杨淑莉, 郑翠玲, 等. 卡瑞利珠单抗联合白蛋白紫杉醇/洛铂新辅助治疗局部晚期食管癌疗效和安全性Ⅱ期临床观察[J]. 中华转移性肿瘤杂志, 2021, 4(3):218-222.
	SONG Q, YANG S L, ZHENG C L, et al. Efficacy and safety of neoadjuvant therapy with camrelizumab combined with albumin-paclitaxel/lobaplatin for locally advanced esophageal cancer:a phase Ⅱ clinical observation[J]. Chinese Journal of Metastatic Cancer, 2021, 4(3):218-222. doi: 10.3760/cma.j.cn101548-20210219-00024.
[21]	姚丽华, 汪光蓉, 蔡燕, 等. miR-18a和miR-21在食管癌中的表达及其对食管癌的诊断价值[J]. 中华肿瘤杂志, 2019, 41(2):107-111.
	YAO L H, WANG G R, CAI Y, et al. The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer[J]. Chinese Journal of Oncology, 2019, 41(2):107-111. doi: 10.3760/cma.j.issn.0253-3766.2019.02.006.
[22]	KAZUYA T, HIROTAKA K, TOMOHIRO A, et al. Anterior gradient 2 regulates cancer progression in TP53 wildtype esophageal squamous cell carcinoma[J]. Oncol Rep, 2021, 46(6):3898-3409. doi: 10.3892/or.2021.8211.
[23]	高晖, 王海鹏, 李冬雷. 沙利度胺对中晚期食管癌患者调强放化疗效果及血清miR-451、miR-21水平的影响[J]. 山东医药, 2021, 61(5):76-79.
	GAO H, WANG H P, LI D L. Influence of thalidomide on the effects of intensity-modulated radiotherapy and chemotherapy and serum miR-451 and miR-21 levels in patients with advanced esophageal cancer[J]. Shandong Medical Journal, 2021, 61(5):76-79. doi: 10.3969/j.issn.1002-266X.2021.05.021.

卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白表达的影响

Effects of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin in patients with advanced esophageal cancer

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 6

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

[1]	秦汉林, 胡长路, 赵亚梅, 牛维纳. 四联方案预防含顺铂方案多日化疗致恶心呕吐的效果和安全性研究[J]. 天津医药, 2024, 52(8): 835-839.
[2]	张丁乾, 高克锋, 熊路遥, 白雪, 聂登科. 卡瑞利珠单抗联合白蛋白结合型紫杉醇对局部晚期食管癌患者的临床疗效[J]. 天津医药, 2024, 52(12): 1256-1261.
[3]	郝凯凯, 王晓敏, 刘峥, 刘东洋, 李静. 藁本内酯调节RhoA/ROCK信号通路对食管癌细胞生物学行为的影响[J]. 天津医药, 2024, 52(11): 1164-1170.
[4]	邵艳梅, 宋洁, 杨梦思, 黄孝慈, 汤昕宇, 胡宪文. 允许性高碳酸血症对老年胸腔镜食管癌根治术患者术后谵妄的影响[J]. 天津医药, 2023, 51(3): 282-285.
[5]	赵雪楠, 郭旭峰, 丁成智, 陈东东, 韦丽瑞, 李晨, 秦贵军, 王娇. 体质量指数对食管鳞癌患者术后并发症和长期预后的影响[J]. 天津医药, 2023, 51(10): 1131-1135.
[6]	白成云, 李忠诚, 李文军, 刘洋. 食管癌患者血清IGFBP-2的表达与营养状态及预后的关系[J]. 天津医药, 2022, 50(6): 622-626.
[7]	赵子龙, 张美云, 高辉, 杜伟, 巴雅尔, 吕艺华△. 安罗替尼联合白蛋白结合型紫杉醇三线治疗非小细胞肺癌的临床疗效和安全性#br#[J]. 天津医药, 2022, 50(5): 539-543.
[8]	闫可 , 魏菀怡 , 沈文斌 , 杜星语 , 王晓斌 , 赵晗君 , 祝淑钗 . 那不勒斯预后评分对临床Ⅲ期食管癌患者预后的预测价值[J]. 天津医药, 2022, 50(4): 408-413.
[9]	李卿, 李轶君, 张国锐. miR-25对食管癌EC109细胞侵袭和迁移能力的影响及临床意义[J]. 天津医药, 2022, 50(4): 357-362.
[10]	曹放, 孙志伟, 史幼梧, 孙婧, 杜丰, 肖艳洁, 余靖, 贾军, 杨颖. ABCC2基因单核苷酸多态性对食管鳞癌术后患者无病生存期的影响[J]. 天津医药, 2022, 50(3): 280-285.
[11]	卢洁, 张芯, 王涛, 杨宁. 环状RNA对房颤患者的影响及其作用机制研究[J]. 天津医药, 2022, 50(3): 333-336.
[12]	李细媛, 朱智鑫, 赵海龙 . BRAF突变型黑色素瘤的耐药性机制及治疗最新研究进展 #br#[J]. 天津医药, 2022, 50(2): 214-219.
[13]	闫可 , 魏菀怡 , 杜星语 , 张雪原 , 沈文斌 , 祝淑钗 . 预后营养指数对老年食管癌患者根治性放疗后长期生存的预测价值[J]. 天津医药, 2021, 49(8): 861-865.
[14]	姆尼热·阿卜力米提, 谭遥△, 王海峰, 刘淑娟, 卢喜, 伊斯刊达尔·阿布力米提. 调强放疗联合索拉非尼治疗肝细胞癌合并门脉癌栓的疗效及预后因素分析#br#[J]. 天津医药, 2021, 49(5): 514-519.
[15]	吕艺华, 赵子龙, 黄革红, 巴雅尔, 杜伟, 高辉, 张美云. 安罗替尼联合伊立替康二线治疗小细胞肺癌的临床疗效及安全性#br#[J]. 天津医药, 2021, 49(4): 436-440.